NurExone Biologic Inc. (TSXV: NRX; OTCQB: NRXBF; FSE: J90) is targeting a potential investigational new drug submission for ExoPTEN during the first half of 2027 as it advances preclinical and manufacturing activities for the experimental therapy.
The timeline was included in NurExone’s second-quarter update, released August 31. ExoPTEN is an exosome-based candidate being developed for acute spinal-cord injury and remains in preclinical development. The company has not submitted an IND or begun human trials.
A central part of the development plan is establishing a U.S. manufacturing process capable of supplying clinical-grade exosomes. In August, NurExone and its subsidiary Exo-Top entered a binding memorandum of understanding with New Jersey-based Made Scientific for a proposed Good Manufacturing Practice manufacturing and commercial-supply relationship.
Technical-documentation transfer has begun, and the companies are targeting production of initial GMP exosome batches during the first half of 2027. However, the arrangement remains subject to a definitive agreement, approved statements of work and the completion of technical, quality and regulatory requirements. The MOU can terminate automatically if a definitive agreement is not reached within six months.
CEO Lior Shaltiel said the steps “are intended to support a potential IND submission in the first half of 2027.”
NurExone also reported new animal-study findings on August 14. According to the company, tissue analysis found statistically higher numbers of myelin-positive cells in ExoPTEN-treated spinal-cord injury models than in untreated controls. The results may support further development, but findings from animal models do not establish safety or efficacy in humans.
For the second quarter, NurExone reported research and development expenses of US$750,000, compared with US$700,000 in the corresponding 2025 period. General and administrative expenses declined to US$930,000 from US$1.13 million, while the quarterly net loss narrowed to US$1.68 million from US$1.85 million.
The company has supplemented its working capital through two recent private placements. A June offering raised approximately C$628,000, followed by C$1.066 million in August. Together, the offerings involved 2,950,899 units, with each unit containing one common share and one warrant. The issued shares diluted existing shareholders, while exercise of the warrants could create additional dilution.
Shareholders are also scheduled to vote September 15 on a proposed share consolidation of up to 30 existing shares for one post-consolidation share. Approval would reduce the number of outstanding shares but would not, by itself, change the company’s underlying value.
Upcoming Catalysts
- A definitive manufacturing agreement with Made Scientific
- Completion of manufacturing technology transfer
- Initial GMP exosome batches targeted for the first half of 2027
- Additional preclinical and regulatory-readiness work
- A potential ExoPTEN IND submission during the first half of 2027
- The September 15 share-consolidation vote
- Additional financing or partnership activity
Sources
- NurExone second-quarter 2026 results — August 31, 2026
- Made Scientific manufacturing MOU — August 12, 2026
- ExoPTEN preclinical tissue-analysis results — August 14, 2026
- August private-placement closing — August 20, 2026
- June private-placement closing — June 30, 2026
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, securities filings and publicly available corporate sources. Securities discussed or referenced include NurExone Biologic Inc. (TSXV: NRX; OTCQB: NRXBF; FSE: J90). Biotech Stocks Daily has not received compensation from NurExone, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include NurExone’s August 31, 2026 financial update, its August 12 manufacturing announcement, its August 14 preclinical update and its June and August financing announcements. Information concerning ExoPTEN, its proposed mechanism, development plans and potential regulatory timeline originated primarily from the company and has not been independently validated by Biotech Stocks Daily.
ExoPTEN remains preclinical. NurExone has not submitted an IND or initiated human trials, and animal-study findings may not predict results in people. The proposed manufacturing relationship remains subject to a definitive agreement and other technical, regulatory and commercial conditions. There is no assurance that GMP batches will be completed on schedule, that an IND will be submitted or accepted, or that ExoPTEN will enter clinical development.
Financial figures are reported in U.S. dollars, while financing amounts are reported in Canadian dollars. The June and August private placements issued common shares and warrants, resulting in immediate and potential additional dilution. The proposed share consolidation remains subject to shareholder and regulatory approvals. No real-time securities prices are included, and readers should verify current market information independently.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
